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Abstract Patientsexperiencingdyspnoea canrequest anadditionaldoseof salmeterolduring thedoseinterval for the
control of their symptoms, although under treatment with salmeterol. In this study we have explored the effects on
respiratory function of an additive dose of salmeterol Diskuss in 15 chronic obstructive pulmonary disease (COPD)
patients in regular treatment with a conventional dose of 50 mg salmeterol. On two different days, patients inhaled
50 mg Diskuss. After 240min, they inhaled additional 50 mg salmeterol Diskuss (salmeterol arm) or placebo Diskuss
(placebo arm). Lung function was controlled before first drug administration and 0?5, 1, 2, 3, 4, 4?5, 6, 8, 10, and 12 h
thereafter.Themean (95% Cl) peak increase in FEV1frombaseline was reached after 4 h in the salmeterol arm (0?174 L;
0?144--0204) and after 5 h (0?141L; 0?115--0?168) in the placebo arm; after12 h, themean (95% Cl) increase in FEV1 from
basal values was still 0?149 L (0?119--0?179) in salmeterol arm, but only 0?041L (0?017--0?064) in placebo arm.Themean
(95% Cl) FEV1AUC0--12h for allpatientswere 2?01 (1?72--2?30) L when salmeterolwas added and1?30 (1?03--1?58) L when
placebowasinhaled.The difference (mean; 95% Cl) betweenthe FEV1AUC0--12h ofthe two arms (0?71L; 0?47--0?95) was
statistically significant (Po0?0001), althoughthe difference (mean; 95% Cl) betweenthe FEV1AUC0--4h of the two treat-
ments (0?08 L;0?02--0?18) wasnot statistically significant (P=0?126).The additionof anextra dose of salmeteroldidnot
significantly increase the heart rate or decrease the SpO2.This study suggests that the addition of an extra dose of
salmeteroldoesnotgiveroomfor furtherincreaseinpeak FEV1, butthe effectof adding salmeterolto salmeterolislargely
additivewhen considering the duration of action and safe.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1279, available online athttp://www.idealibrary.comon
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Salmeterol is a long-acting b2-agonist for inhalation, cur-
rently being used in the management of COPD (1^4). Its
recommended dosage in patients with COPD is 50mg
twice daily approximately 12h apart (5). Higher dosages
areunlikely to provide further improvement in lung func-
tion (6). However, although it is currently not approved
for being used on demand to relieve acute symptoms
(5), some patients, experiencing dyspnoea while in regu-
lar treatment with salmeterol, may be tempted to use
this controller b2-agonist as a reliever bronchodilator.Received18 November 2001and accepted 28 November 2001.
Correspondence should be addressed to: Mario Cazzola,Via del
ParcoMargherita 24, 80121Napoli, Italy.Fax: +39 0817473331;
E-mail: mcazzola@qubisoft.itConsequently, they take a higher that recommended
dose.
In this study we have explored the e¡ects on respira-
tory function of an additive dose of 50mg salmeterol
Diskuss in COPD patients treated with a conventional
dose of 50mg salmeterol Diskuss. Moreover, we have
also investigated if this addition of salmeterolwas safe.
PATIENTSANDMETHODS
Patients
Fifteen patients with COPD, but in a stable phase of the
disease and in regular treatment with the conventional
dose of 50mg salmeterol, participated in the study after
giving their informed consent. All work was conducted
FIG. 1. The actual data (mean7SEM) of FEV1before and at dif-
ferent times after the administration of 50 mg salmeterol. At
240min, patients inhaled an extra dose of 50 mg salmeterol or
placebo. : SLM+SLM; : SLM+PL.
440 RESPIRATORYMEDICINEaccording to the rules of the Declaration of Helsinki. An
independent review board for human studies approved
the protocol, and each patient gave informed consent to
all procedures.
All patients ful¢lled the criteria proposed by the
American Thoracic Society (7). Inclusion criteria were:
460yrs of age, current or former smokers (410 pack-
yrs) without a history of asthmatic attacks, reporting
either chronic coughwith orwithout sputumproduction
or dyspnoea when walking quietly on level ground, or
both, had had no change in symptom severity or treat-
ment in the preceding 4 weeks, and had a FEV165% of
predicted normal and a FVC70% after bronchodilators
had been withheld for 24h. Patients with a history of
asthma, allergic rhinitis, atopy, or with a total blood
eosinophil count over 400mm3 and, eventually, a
positive methacholine challenge were not considered
as COPD patients. Patients with sign of a respiratory
tract infection in the month preceding the study, a
resting PaO2 of less than 60mmHg, or use of long-term
oxygen therapy were not eligible.
Study design
This was a randomized, double blind, and crossover
study, taking place over two consecutive days. On two
di¡erent days, patients inhaled 50mg salmeterol Dis-
kuss. After 240min they inhaled additional 50mg salme-
terol Diskuss (salmeterol arm) or placebo Diskuss
(placebo arm). Lung function was controlled before ¢rst
drug administration and 0?5,1, 2, 3, 4, 4?5, 6, 8,10, and12h
thereafter. Spirometric testingwasperformedaccording
to the procedures described in the 1987 update of the
American Thoracic Society’s guidelines on standardiza-
tion of spirometry (8).On each occasion, threemeasure-
ments were taken and the highest inspiratory capacity
(IC), and FEV1, obtained from one or other of the curves,
were kept for analysis. Contemporaneously, we also
measured oxygen saturation by pulse oximetry (SpO2)
and heart rate.
As an expression of the total e¡ect of each treatment,
the areas under the FEV1 response^time curves (AUC)
were calculated for each patient.
Oral bronchodilators were not permitted for 1-week
before and during the study; inhaled short- and long-
acting bronchodilator agents were not permitted for at
least 6 h and12hprior to each test, respectively.Patients
were also requested not to consume cola drinks, co¡ee
or tea and not to smoke in the hours before and during
the investigation.
Analysis of data
Spirometric data for each treatmentwere analysedusing
the Student’s t-test for paired variables. Mean responseswere also comparedbymultifactorial analysis of variance
(ANOVA) to establish any signi¢cant overall e¡ect be-
tween the two treatment. In thepresence of a signi¢cant
overall ANOVA, Duncan’s multiple range testing with
95% con¢dence limits was used to identify where di¡er-
enceswere signi¢cant. Aprobability level of Po0?05was
considered as signi¢cant for all tests.The areas under the
FEV1 response/time curves were analyzed by the trape-
zoidal rule.
RESULTS
All patients completed the 2-day study. There were no
signi¢cant di¡erences between the baseline spirometric
values of the two treatment groups (P40?05).
The mean peak increase in FEV1 from baseline was
reached after 4h in the salmeterol arm (0?174L; 95%
Cl: 0?144^0204) and after 5h (0?141L; 95% Cl:
0?115^0?168) in the placebo arm (Fig. 1). After 12h, the
mean increase in FEV1 from basal values was still 0?149L
(95% Cl: 0?119^0?179) in salmeterol arm, but only 0?041L
(95% Cl: 0?017^0?064) in placebo arm. The mean FEV1
AUC0 1^2h for all patients were 2?01 (95% Cl:1?72 2^?30) L
when salmeterol was added and1?30 (1?03 1^?58) L when
placebo was inhaled (Fig. 2). The di¡erence between
the FEV1 AUC0 1^2h of the two arms (0?71L; 95% Cl:
0?47^0?95) was statistically signi¢cant (Po0?0001),
although the di¡erence (mean; 95% Cl) between the
FEV1 AUC0^4h of the two treatments (0?08L: 95% C:
0?02^0?18) was not statistically signi¢cant (P=0?126)
(Fig. 2). The mean peak increase in IC from baseline
was reached after 5h in the salmeterol arm (0?411L;
95% Cl: 0?254^0?568) and after 2h (0?359L; 95% Cl:
0?257^0?461) in the placebo arm (Fig. 3). After 12h, the
mean increase in FEV1 from basal values was 0?284L
FIG. 2. The actualdata (mean7SEM) of IC before and at di¡er-
ent times after the administration of 50 mg salmeterol. At
240min, patients inhaled an extra dose of 50 mg salmeterol or
placebo. : SLM+SLM; : SLM+PL.
FIG. 3. Mean (7SEM) AUC0 1^2hs and AUC0 4^hs after the ad-
ministration of 50 mg salmeterol. At 240min, patients inhaled an
extra dose of 50 mg salmeterol or placebo. : SLM+SLM;
:SLM+PL.
FIG. 4. The actual data (mean7SEM) of heart rate (HR) and
pulse oximetry (SpO2) before andatdi¡erenttimes after the ad-
ministration of 50 mg salmeterol. At 240min, patients inhaled an
extra dose of 50 mg salmeterol or placebo. : SLM+SLM;
:SLM+PL.
EFFECTSOF INCREASEDSALMETEROLDISKUSsDOSAGE 441(95% Cl: 0?164^0?404) in salmeterol arm, and 0?098L
(95% Cl: 0?042^0?154) in placebo arm.The addition of an
extra dose of salmeterol didnot signi¢cantly increase the
heart rate of decrease the SpO2 (Fig. 4).
DISCUSSION
The results of this study suggests that the addition of an
extra dose of salmeterol to patients with stable COPD,
who are under regular treatment with the recom-
mended dosage of salmeterol, does not give room for
further increase inpeak FEV1.However, the e¡ectof add-
ing salmeterol to salmeterol is largely additivewhen con-
sidering the duration of action.
The lack of further bronchodilation that we have
observed after the inhalation of an extra dose of
salmeterol is probably due to the fact that our patients,who were in a stable phase of their disease, were at
the top of their bronchodilation after the inhalation of
the ¢rst conventional dose of his bronchodilator. We
must highlight that each patient su¡ering from stable
COPDhashis own optimal lung function level, amaximal
spirometry value for FEV1 that he can never exceed (9).
This is in the nature of illness, with irreversible lung
changes.Below this lung function level there exists a dai-
ly variation of respiratory function onwhich bronchodi-
lators can act.
It should also be hypothesised that, since salmeterol
is a partial agonist, it might act as a b2-antagonist in
the presence of another b-agonist (in this case the same
salmeterol) (10). We do not believe that this is a real
possibility because we have previously demonstrated
that the partial agonism of salmeterol has no in£uence
on the bronchodilator e¡ect. In fact, a pre-treatment
with a conventional dose of this long-acting b2-agonist
did not reduce the possibility of inducing a further
bronchodilation with another b-agonist in patients who
were su¡ering from COPD and presented a partially
reversible bronchospasm (11).
442 RESPIRATORYMEDICINEGenerally, physicians suggest avoiding salmeterol for
use on demandbecause there is no scienti¢cdocumenta-
tion of the e¡ects of this bronchodilator when it is as-
sumed in this way (12). Nevertheless, in real life many
dyspnoic patients autonomously take extra doses of sal-
meterol in absence of a medical prescription because,
very often, it is the only available bronchodilator. This
event is not frequent, because salmeterol induces not
only bronchodilation measured by the changes in FEV1
that usually lasts more than12h even in COPD patients
(3), but also a signi¢cantly greater reductions in dys-
pnoea (12). However, unfortunately, there are no signi¢-
cant correlations between changes in dyspnoea and
changes in physiologic variables in patients with COPD
(13). In fact, several patients have a bronchodilator re-
sponse only or a dyspnoea response only, and this prob-
ably because dyspnoea and lung function represent
di¡erent constructs (12).Moreover, evenwhen broncho-
dilator induces both improvements in lung function and
reductions in dyspnoea, it does not elicit signi¢cant
change inwalkingdistance or peakexerciseperformance
(14).Therefore, a dyspnoic patient who has a bronchodi-
lator response only could be tried to assume additional
doses of his bronchodilator in the hope of relieving
dyspnoea when he is unable to perceive bronchodilation
ormust perform an exercise.
The tolerabilityof salmeterol is usuallygood (15), but it
is impossible to exclude that an additional dose of this
drug might include side e¡ects such as skeletal muscle
tremors, headache, nausea, vomiting, palpitations, in-
crease in cardiac frequency, and transient decrease in
PaO2. These are typical adverse e¡ects of b2-agonists,
mainly when they are administered at a dosage higher
than conventional (16).
Our study not only has con¢rmed that salmeterol is
an e¡ective bronchodilator in patients with COPD, but
it has also rea⁄rmed the absolute manageability of this
drug that has widely been documented. For example,
Tranfa et al. (17) have shown that salmeterol, adminis-
tered in regular and high doses for a short period, does
not cause signi¢cant cardiovascular e¡ects in both
normal subjects and patients with reversible airway
obstruction. Moreover, Khoukaz and Gross (18) have
documented that salmeterol induces a small and transi-
ent decrease in PaO2 below baseline values in patients
with COPD. However, this decline was small, transient,
and of doubtful clinical signi¢cant.
The lack of e¡ects on heart rate and SpO2 that we
have observed in this study is a ¢nding that can reassure
physicians.On the other hand, several studies have docu-
mented that at the dose of 100 mg, the total does admi-
nistered in present study, salmeterol is usually well
tolerated by themajority of patients (19, 20)
This study, even if limited by the small number of
cases, clearly points out that those patients with COPD
who are under regular treatment with salmeterol, fromwhich they do not draw, however, the maximum bene¢t
because theyunable to perceivebronchodilation ormust
perform anexercise, canuse an additional dose of salme-
terol.However, theymustnotexpect an improvementof
bronchodilation from this dose, but, rather, the suste-
nance of that already reached after the assumption of
the ¢rst dose. There is, nevertheless, the real risk that
patients can judge salmeterol as a rescue medication if
they are not adequately informed. In this case, they could
use the drug freely, without a real limit of the dose, as
they usually do with salbutamol. Therefore, it is funda-
mental thatpatients understand that salmeterol is an im-
portant drug for the management of their illness, but it
must always be taken according to themedical prescrip-
tion. In the case of a sudden need of furtherbronchodila-
tion, an extra does can be allowed, but this must always
be considered an exception and not the rule.This will be
a basic concept at least until the frequent use of extra
doses of salmeterol during a regular treatment with the
same long-acting b2-agonist is shown to be e¡ective and
safe.
REFERENCES
1. Cazzola M, Matera MG. Should long-acting b2-agonists be consi-
dered an alternative ¢rst choice option for the treatment of stable
COPD? Respir Med1999; 93: 227 2^29.
2. L˛tvall J.Pharmacologyof bronchodilators used in the treatmentof
COPD.Respir Med 2000; 94 (Suppl E): S6 S^10.
3. CazzolaM,DonnerCF.Long-acting b2-agonists in themanagement
of stable chronic obstructive pulmonary disease. Drugs 2000; 60:
307 3^20.
4. NHLBI/WHO.Global strategy for the diagnosis, management and
prevention of chronic obstructive pulmonary disease.Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD).NHLBI/WHO
workshop report 2001.
5. Glaxo Wellcome Inc. Serevent (salmeterol xinafoate) inhalation
aerosol. Product information.GlaxoWellcome Inc.ResearchTrian-
gle Park (NC), July 2000.
6. Cazzola M,Matera MG, Santangelo G, et al. Salmeterol and formo-
terol in partially reversible severe chronic obstructive pulmonary
disease: a dose-response study.Respir Med1995; 89: 357 3^62.
7. AmericanThoracic Society. Standards for the diagnosis and care of
patients with chronic obstructive pulmonary disease. Am J Respir
Crit Care Med1995; 152: 77S 1^21S.
8. AmericanThoracic Society. Standardization of spirometry - 1987
update. Am Rev Respir Dis1987; 136:1285 1^298.
9. Hansen G, AndrewwM, Bjermer L, et al.Retningslinjer fur utredn-
ing og behandling av kronisk obstruktiv lungesykdom.Tidsskr Nor
Laegeforen1995; 115: 710 7^13.
10. Lipworth BJ,Grove A.Evaluation of partial b-adrenoceptor agonist
activity.Br J Clin Pharmacol1997; 43: 9 1^4.
11. Cazzola M, Di Perna F, Noschese P, et al. E¡ects of a pre-treatment
with conventional doses of formoterol, salmeterol or oxitropium
bromide on the dose-response curves to salbutamol in patients
su¡ering from partially reversible COPD. Eur Respir J 1998; 11:
1337 1^341.
12. Ramirez-Venegas A, Ward J, Lentine T, et al. Salmeterol reduces
dyspnoea and improves lung function in patientswith COPD. Chest
1997; 112: 336 3^40.
EFFECTSOF INCREASEDSALMETEROLDISKUSsDOSAGE 44313. Wolkove N, Dajczman E, Colacone A, et al. The relationship
between pulmonary function and dyspnoea in obstructive lung
disease.Chest1989; 96:1247^ 1251.
14. Mahler DA, Donohue JF, Barbee RA, et al. E⁄cacy of salmeterol
xinafoate in the treatment of COPD.Chest1999; 115: 957 9^65.
15. Jarvis B, Markham A. Inhaled salmeterol: a review of its e⁄cacy
in chronic obstructive pulmonary disease. Drugs Aging 2001; 18:
441^472.
16. LulichKM,GoldieRG,RyanG, etal. Adversereactions tob2-agonist
bronchodilators.Med Toxicol1986; 1: 286 2^99.
17. Tranfa CM, Pelaia G,Germbiale RD, et al. Short-term cardiovascular
e¡ects of salmeterol.Chest1998; 113:1272 1^276.18. Khoukaz G,Gross NJ. E¡ects of salmeterol on arterial blood gases
inpatientswith stable chronic obstructivepulmonarydisease com-
parison with albuterol and ipratropium. Am J Respir Crit Care Med
1999; 160:1028 1^030.
19. BoydG,Morica AH,Pounsford JC, et al. An evaluation of salmeterol
in the treatment of chronic obstructive pulmonary disease
(COPD).Eur Respir J1997; 10: 815^821.
20. L˛tvall J, Lunde H, Svedmyr N.Onset of bronchodilation and ¢nger
tremor inducedby salmeterol and salbutamol in asthmatic patients.
Can Respir J1998; 5:191 9^4.
